| Ye, Dingwei |
ACCRUE, NCT04490993: Safety and Efficacy of APL-1202 in Combination With Epirubicin Hydrochloride Versus Epirubicin Hydrochloride Alone in Intermediate and High-risk Chemo-refractory Non-muscle Invasive Bladder Cancer (NMIBC) Patients |
|
|
| Active, not recruiting | 3 | 359 | RoW | APL-1202 in combination with Epirubicin, Placebo in combination with Epirubicin | Jiangsu Yahong Meditech Co., Ltd aka Asieris | Non-muscle Invasive Bladder Cancer | 05/22 | 05/22 | | |
NCT04859751: Study of VB4-845 Injection for Treating Patients With Non-muscle Invasive Bladder Cancer |
|
|
| Recruiting | 3 | 53 | RoW | VB4-845 Injection | Qilu Pharmaceutical Co., Ltd. | Non-Muscle Invasive Bladder Cancer | 06/22 | 12/23 | | |
CHART, NCT03520478: A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer |
|
|
| Active, not recruiting | 3 | 654 | Europe, RoW | SHR3680, Bicalutamide | Jiangsu HengRui Medicine Co., Ltd. | Prostate Cancer, Hormone-Dependent Prostate Cancer | 04/23 | 04/25 | | |
RATIONALE-310, NCT03967977: Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma |
|
|
| Recruiting | 3 | 420 | RoW | Tislelizumab, BGB-A317, Placebo, Cisplatin, Gemcitabine Hydrochloride, Carboplatin | BeiGene | Urothelial Carcinoma | 06/27 | 06/27 | | |
NCT06592326: 9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer |
|
|
| Recruiting | 3 | 460 | RoW | 9MW2821, Toripalimab, Toripalimab injection, Gemcitabine, Gemcitabine Hydrochloride for Injection, Cisplatin/Carboplatin, Cisplatin for injection/Carboplatin Injection | Mabwell (Shanghai) Bioscience Co., Ltd. | Urothelial Carcinoma | 09/27 | 12/28 | | |
Ascertain, NCT04736394: A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in naïve Intermediate-risk NMIBC Patients |
|
|
| Recruiting | 3 | 800 | RoW | APL-1202, Epirubicin Hydrochloride | Jiangsu Yahong Meditech Co., Ltd aka Asieris | Non-muscle Invasive Bladder Cancer | 03/25 | 12/25 | | |
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) |
|
|
| Active, not recruiting | 3 | 900 | Europe, Canada, Japan, US, RoW | Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib | Eli Lilly and Company | Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6 | 02/24 | 10/27 | | |
NCT04691804 / 2020-006063-28: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer |
|
|
| Active, not recruiting | 3 | 496 | Europe, US, RoW | Fuzuloparib , Abiraterone acetate and Prednisone, SHR3162, Fuzuloparib Placebo， Abiraterone acetate and Prednisone | Jiangsu HengRui Medicine Co., Ltd. | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 12/26 | 12/26 | | |
NCT05009290: A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy |
|
|
| Recruiting | 3 | 1256 | RoW | SHR3680, Placebo | Jiangsu HengRui Medicine Co., Ltd. | Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy | 10/27 | 10/31 | | |
FRUSICA-2, NCT05522231: Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma |
|
|
| Active, not recruiting | 2/3 | 265 | RoW | fruquintinib+sintilimab, HMPL-013 + IBI308, axitinib / everolimus, fruquintinib, HMPL-013 | Hutchmed | Advanced Renal Cell Carcinoma | 01/25 | 03/25 | | |
NCT04718584: the Efficacy and Safety of LDP in Patients With Urinary and Male Genital Tumors |
|
|
| Recruiting | 2 | 127 | RoW | Human Anti-PD-L1 Monoclonal Antibody Injection (LDP), LDP | Dragonboat Biopharmaceutical Company Limited, Fudan University | Bladder Cancer, Renal Carcinoma, Advanced Penile Carcinoma | 11/22 | 11/23 | | |
| Recruiting | 2 | 265 | RoW | SHR-1210, Camrelizumab, Famitinib, Famitinib Malate Capsule | Jiangsu HengRui Medicine Co., Ltd. | Renal Cell Carcinoma, Urothelial Carcinoma, Cervical Cancer, Ovarian Cancer Recurrent, Endometrial Cancer | 12/22 | 12/22 | | |
NCT04738630: Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer |
|
|
| Recruiting | 2 | 110 | RoW | HX008 | Taizhou Hanzhong biomedical co. LTD | Bladder Cancer | 12/22 | 12/23 | | |
NCT06222125: A Study of HB0025 Injection in Patients With Advanced Renal Cancer |
|
|
| Recruiting | 2 | 100 | RoW | HB0025, Recombinant humanized anti-programmed cell death-ligand 1（Anti-PD-L1） monoclonal antibody-VEGFR1 fusion protein | Huabo Biopharm Co., Ltd. | Renal Cancer | 01/25 | 12/25 | | |
NCT06354231: DV Combined With Toripalimab for Renal Preservation in Solitary Kidney or Renal Insufficiency or Bilateral Multiple UTUC |
|
|
| Recruiting | 2 | 20 | RoW | DV, RC48, Toripalimab, JS001, Laser surgery | Fudan University | Renal Insufficiency, Upper Urinary Tract Urothelial Carcinoma, Solitary Kidney | 12/26 | 12/26 | | |
NCT06187506: Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer |
|
|
| Recruiting | 2 | 20 | RoW | Disitamab vedotin, RC48, Bacillus Calmette Guerin Vaccine, BCG | Fudan University | Non-muscle Invasive Bladder Cancer, HER-2 Protein Overexpression | 04/26 | 01/27 | | |
NCT06211790: Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma |
|
|
| Recruiting | 2 | 66 | RoW | Anlotinib, Everolimus and Tislelizumab | Fudan University | Kidney Cancer, Renal Cell Carcinoma, Renal Clear Cell Carcinoma | 12/25 | 12/26 | | |
OMPCa-ENSURE, NCT05212857: Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer |
|
|
| Recruiting | 2 | 160 | RoW | Leuprolide acetate, Enantone, Goserelin acetate, Zoladex, Triptorelin acetate, Diphereline, Degarelix acetate, Firmagon, Abiraterone acetate, ZYTIGA, Apalutamide, ERLEADA, Enzalutamide, Xtandi, Local treatment for primary lesion, Radiotherapy for primary lesion, Radiotherapy for metastatic lesion, Stereotactic body radiation therapy or proton and heavy ion radiation therapy | Fudan University | Prostate Cancer | 02/24 | 09/24 | | |
| Recruiting | 2 | 52 | RoW | BL-B01D1, PD-1 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Urothelial Carcinoma | 05/26 | 05/26 | | |
NCT06690697: Combination of Toripalimab and JS004 Therapy for ccRCC |
|
|
| Recruiting | 2 | 80 | RoW | JS004, Toripalimab, Axitinib, Sorafenib | Fudan University | Clear Cell Renal Cell Carcinoma | 06/26 | 12/26 | | |
AK104-213, NCT05256472: A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma |
|
|
| Recruiting | 2 | 70 | RoW | AK104, axitinib | Akeso | Renal Cell Carcinoma, First-line Treatment | 07/24 | 12/25 | | |
| Recruiting | 2 | 200 | RoW | TURP, Standard Medical Therapy | Fudan University | Metastatic Prostate Cancer | 09/26 | 12/26 | | |
HS-20093-202, NCT06001255: ARTEMIS-003: HS-20093 in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) and Advanced Solid Tumors |
|
|
| Recruiting | 2 | 120 | RoW | HS-20093 | Hansoh BioMedical R&D Company | Metastasis Castration Resistant Prostate Cancer(mCRPC) | 12/24 | 12/25 | | |
NCT06738745: Study of HRS-2189 Combined HRS-5041 in Prostate Cancer |
|
|
| Not yet recruiting | 2 | 90 | RoW | HRS-2189, HRS-5041 | Fudan University | Prostate Cancer Metastatic Disease | 01/27 | 08/27 | | |
NCT05785039: A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors |
|
|
| Recruiting | 2 | 76 | RoW | BL-B01D1 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Urinary System Tumor, Solid Tumor | 04/25 | 04/25 | | |
NCT05965856: A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors |
|
|
| Recruiting | 2 | 52 | RoW | BL-B01D1, SI-B003 | Sichuan Baili Pharmaceutical Co., Ltd. | Urothelial Carcinoma, Solid Tumor | 12/25 | 12/25 | | |
NCT05775874: A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC |
|
|
| Recruiting | 2 | 80 | RoW | AZD4547, FGFR1/2/3/4 inhibitor, Tislelizumab, PD1 inhibitor | Abbisko Therapeutics Co, Ltd | Urothelial Carcinoma | 09/25 | 12/25 | | |
| Recruiting | 2 | 240 | Europe, Canada, US, RoW | SKB264, Pembrolizumab, Keytruda | Klus Pharma Inc., Myriad Genetics, Inc., Discovery Life Sciences, LLC, Ventana Medical Systems, Inc, Frontage Laboratories, Inc. | Solid Tumor | 11/26 | 12/27 | | |
NCT05086666: A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547 |
|
|
| Recruiting | 1b/2 | 108 | RoW | AZD4547, ABSK091 | Abbisko Therapeutics Co, Ltd | Urothelial Carcinoma | 08/23 | 05/24 | | |
NCT06732531: Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer |
|
|
| Recruiting | 1/2 | 48 | RoW | BH011, Docetaxel | Zhuhai Beihai Biotech Co., Ltd | Bladder Cancer, Non Muscle Invasive | 12/25 | 12/25 | | |
NCT04706598: Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment |
|
|
| Active, not recruiting | 1/2 | 25 | RoW | Camrelizumab, SHR-1210 | Fudan University, Shanghai Shen Kang Hospital Development Center | Urinary Bladder Neoplasms, Immunotherapy | 07/24 | 12/24 | | |
ANTICIPATE, NCT04813107: A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer |
|
|
| Recruiting | 1/2 | 79 | US, RoW | APL-1202 in combination with tislelizumab, Tislelizumab alone | Jiangsu Yahong Meditech Co., Ltd aka Asieris | Muscle Invasive Bladder Cancer | 11/23 | 03/24 | | |
NCT06139575: Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer |
|
|
| Recruiting | 1/2 | 90 | RoW | Lutetium Lu 177 JH020002 Injection | Bivision Pharmaceuticals, Inc. | Prostate Cancer | 05/26 | 07/27 | | |
| Recruiting | 1/2 | 134 | US, RoW | PRO1160 | ProfoundBio US Co. | Renal Cell Carcinoma, Nasopharyngeal Carcinoma, Non Hodgkin Lymphoma | 11/26 | 03/27 | | |
NCT06588179: SHR-1501 Combined With SHR-2005 for High-Risk Non-Muscle Invasive Bladder Cancer Which is Not Completely Resectable by TURBt |
|
|
| Not yet recruiting | 1/2 | 58 | RoW | SHR-1501+SHR-2005 | Fudan University | NMIBC | 10/27 | 10/27 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
NCT06081686: Study of [177Lu] Lu-XT033 Injection in Patients With Metastatic Prostate Cancer |
|
|
| Recruiting | 1/2 | 32 | RoW | Phase I:[177Lu]Lu-XT033 Injection, Phase II:[177Lu]Lu-XT033 Injection | Sinotau Pharmaceutical Group | Prostate Cancer | 12/25 | 12/25 | | |
| Completed | 1 | 12 | RoW | BH002 | Zhuhai Beihai Biotech Co., Ltd | Solid Tumours | 03/23 | 03/23 | | |
| Recruiting | 1 | 120 | RoW | TQB3720 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Metastatic Castration-resistant Prostate Cancer | 05/23 | 05/23 | | |
NCT06182735: CD70-targeted CAR-NKT Cells(CGC729) Therapy in the Renal Cell Carcinoma |
|
|
| Recruiting | 1 | 9 | RoW | Cyclophosphamide + Fludarabine + Infusion of CAR-NKT Cells | Fudan University | Renal Cell Carcinoma | 01/25 | 01/25 | | |
NCT06427291: Clinical Study of T3011 Intravesical Instillation for Treatment of NMIBC Patients |
|
|
| Recruiting | 1 | 20 | RoW | Herpes virus T3011 injection | Fudan University | Bladder Cancer | 12/25 | 12/25 | | |
NCT05099536: 3D011-08 Monotherapy in Subjects With Advanced Solid Tumors |
|
|
| Withdrawn | 1 | 93 | RoW | 3D011-08 | 3D Medicines (Beijing) Co., Ltd. | Solid Tumor, Adult | 09/23 | 09/23 | | |
NCT06186414: A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC |
|
|
| Recruiting | 1 | 152 | RoW | SIM0237, SIM0237 and BCG | Jiangsu Simcere Pharmaceutical Co., Ltd., Shanghai Xianxiang Medical Technology Co., Ltd. | Non-Muscle-Invasive Bladder Cancer (NMIBC) | 01/27 | 12/30 | | |
NCT06609005: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients with Advanced Metastatic Castration Resistant Prostate Cancer |
|
|
| Recruiting | 1 | 66 | US, RoW | INV-9956 | Shenzhen Ionova Life Sciences Co., Ltd. | Advanced Metastatic Castration Resistant Prostate Cancer | 04/26 | 03/27 | | |
NCT05843305: A Study of BPI-452080 in Subjects With Solid Tumors |
|
|
| Not yet recruiting | 1 | 87 | RoW | BPI-452080 | Betta Pharmaceuticals Co., Ltd. | Solid Tumor, Renal Cell Carcinoma, Von Hippel-Lindau Disease | 03/25 | 10/25 | | |
NCT06094777: A Study of HY-0102 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 50 | RoW | HY-0102 | Shanghai YingLi Pharmaceutical Co. Ltd. | Advanced Solid Tumor | 06/25 | 12/25 | | |
NCT05670691: a Study of Combined mpMRI and PSMA PET/CT for Highly Suspicious Patients Performing Radical Prostatectomy Without Biopsy |
|
|
| Not yet recruiting | N/A | 71 | NA | | Fudan University | Prostatic Neoplasms, Prostatectomy, Prostate Biopsy | 12/24 | 03/25 | | |
